BIORPHEN (phenylephrine hydrochloride) by Dr. Reddy's Laboratories is α-1 adrenergic receptor agonist. First approved in 2019.
Drug data last refreshed 6h ago · AI intelligence enriched 5d ago
BIORPHEN is an intravenous solution of phenylephrine hydrochloride, an α-1 adrenergic receptor agonist approved by the FDA in October 2019. It is indicated for acute hypotension management in critical care and perioperative settings. The drug works by stimulating α-1 adrenergic receptors to induce vasoconstriction and increase blood pressure.
Product is in peak commercial stage with established hospital formulary presence; team likely focused on market penetration and cost management rather than growth expansion.
α-1 adrenergic receptor agonist.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Evaluation of Efficacy and Safety of Tablets of Paracetamol, Dimethindene Maleate and Phenylephrine Hydrochloride in Reducing Symptoms of Common Cold and Flu
Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study
Safety of Phenylephrine Hydrochloride, Acetaminophen, Dimethindene Maleate Compared to Phenylephrine Hydrochloride Alone in Healthy Volunteers
Consumer Preference Study of Two Formulations of Phenylephrine Hydrochloride (Study CL2008-15)(P07530)(COMPLETED)
Worked on BIORPHEN at Dr. Reddy's Laboratories? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on BIORPHEN offers stable, specialized experience in hospital-based critical care commercialization with focus on cost management, formulary strategy, and ICU relationships rather than primary demand generation. Career trajectory is suited for professionals targeting hospital/institutional sales or health economics roles where vasopressor familiarity and critical-care credibility are valued assets.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo